Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150760 · ClinicalTrials.gov registry record
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
A clinical trial, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- 7,050
- Enrollment target
NCT01150760 is a clinical trial that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 7,050 participants.
The verdict
NCT01150760 has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- 7,050 participants
- Enrollment target
Study Summary
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The primary objective of this retrospective observational trial is to assess postoperative morbidity and mortality as reported during the index hospitalization for bowel resection and 15/30-day readmissions of alvimopan vs. non-alvimopan matched patients in the combined Premier/Care Science database(a large medical claims database).
Interventions
- DRUG Alvimopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,050 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-08 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150760
The ClinicalTrials.gov registry entry for NCT01150760 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alvimopan is the first listed.
NCT01150760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150760 about?
NCT01150760 is a clinical study titled "Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database". Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The primary objective of this retrospective observational trial is to ...
What is the current status of trial NCT01150760?
This trial is currently completed. The enrollment target is 7,050 participants. The study started on 2010-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01150760?
The interventions under investigation include: Alvimopan (DRUG).
Who is sponsoring clinical trial NCT01150760?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.